These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22860161)

  • 1. ACS chemical neuroscience molecule spotlight on RG1678.
    Hopkins CR
    ACS Chem Neurosci; 2011 Dec; 2(12):685-6. PubMed ID: 22860161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey.
    Eddins D; Hamill TG; Puri V; Cannon CE; Vivian JA; Sanabria-Bohórquez SM; Cook JJ; Morrow JA; Thomson F; Uslaner JM
    Psychopharmacology (Berl); 2014 Feb; 231(3):511-9. PubMed ID: 24051602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient.
    Pinard E; Borroni E; Koerner A; Umbricht D; Alberati D
    Chimia (Aarau); 2018 Aug; 72(7):477-484. PubMed ID: 30158010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schizophrenia drug gets negative results for negative symptoms.
    Kingwell K
    Nat Rev Drug Discov; 2014 Apr; 13(4):244-5. PubMed ID: 24687052
    [No Abstract]   [Full Text] [Related]  

  • 5. Glycine transport inhibitors in the treatment of schizophrenia.
    Javitt DC
    Handb Exp Pharmacol; 2012; (213):367-99. PubMed ID: 23027421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.
    Pinard E; Alanine A; Alberati D; Bender M; Borroni E; Bourdeaux P; Brom V; Burner S; Fischer H; Hainzl D; Halm R; Hauser N; Jolidon S; Lengyel J; Marty HP; Meyer T; Moreau JL; Mory R; Narquizian R; Nettekoven M; Norcross RD; Puellmann B; Schmid P; Schmitt S; Stalder H; Wermuth R; Wettstein JG; Zimmerli D
    J Med Chem; 2010 Jun; 53(12):4603-14. PubMed ID: 20491477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutics: Negative feedback.
    Dolgin E
    Nature; 2014 Apr; 508(7494):S10-1. PubMed ID: 24695327
    [No Abstract]   [Full Text] [Related]  

  • 9. Structural insights into the inhibition of glycine reuptake.
    Shahsavar A; Stohler P; Bourenkov G; Zimmermann I; Siegrist M; Guba W; Pinard E; Sinning S; Seeger MA; Schneider TR; Dawson RJP; Nissen P
    Nature; 2021 Mar; 591(7851):677-681. PubMed ID: 33658720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.
    Alberati D; Moreau JL; Lengyel J; Hauser N; Mory R; Borroni E; Pinard E; Knoflach F; Schlotterbeck G; Hainzl D; Wettstein JG
    Neuropharmacology; 2012 Feb; 62(2):1152-61. PubMed ID: 22138164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
    Singer P; Dubroqua S; Yee BK
    Curr Pharm Des; 2015; 21(26):3771-87. PubMed ID: 26205290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bitopertin: the good news and bad news.
    Goff DC
    JAMA Psychiatry; 2014 Jun; 71(6):621-2. PubMed ID: 24696065
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
    Dunayevich E; Buchanan RW; Chen CY; Yang J; Nilsen J; Dietrich JM; Sun H; Marder S
    Schizophr Res; 2017 Apr; 182():90-97. PubMed ID: 27789188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
    Hofmann C; Pizzagalli F; Boetsch C; Alberati D; Ereshefsky L; Jhee S; Patat A; Boutouyrie-Dumont B; Martin-Facklam M
    Psychopharmacology (Berl); 2016 Jul; 233(13):2429-39. PubMed ID: 27178435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico evidence of bitopertin's broad interactions within the SLC6 transporter family.
    de Carvalho GA; Tambwe PM; Nascimento LRC; Campos BKP; Chiareli RA; Junior GPN; Menegatti R; Gomez RS; Pinto MCX
    J Pharm Pharmacol; 2024 Sep; 76(9):1199-1211. PubMed ID: 38982944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.
    Pinard E; Alberati D; Borroni E; Fischer H; Hainzl D; Jolidon S; Moreau JL; Narquizian R; Nettekoven M; Norcross RD; Stalder H; Thomas AW
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5134-9. PubMed ID: 18752953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of GlyT1 inhibition on erythropoiesis and iron homeostasis in rats.
    Winter M; Funk J; Körner A; Alberati D; Christen F; Schmitt G; Altmann B; Pospischil A; Singer T
    Exp Hematol; 2016 Oct; 44(10):964-974.e4. PubMed ID: 27403535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.
    Chaki S; Shimazaki T; Karasawa J; Aoki T; Kaku A; Iijima M; Kambe D; Yamamoto S; Kawakita Y; Shibata T; Abe K; Okubo T; Sekiguchi Y; Okuyama S
    Psychopharmacology (Berl); 2015 Aug; 232(15):2849-61. PubMed ID: 25869273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography.
    Borroni E; Zhou Y; Ostrowitzki S; Alberati D; Kumar A; Hainzl D; Hartung T; Hilton J; Dannals RF; Wong DF
    Neuroimage; 2013 Jul; 75():291-300. PubMed ID: 22178811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.